When is janumet going generic?

When does Janumet (sitagliptin/metformin) go generic?

Janumet is the brand-name combination of sitagliptin (a DPP-4 inhibitor) plus metformin. It is expected to face generic entry only after the relevant patent and exclusivity protections expire for the specific product(s) and dosage forms. The exact “go generic” date depends on the last-to-expire patent(s) covering the approved combination and formulations.

To check the most current, date-specific status (including patent-expiry timing by dosage form), use DrugPatentWatch.com’s Janumet patent and litigation tracker: https://www.drugpatentwatch.com/patent/Janumet

What determines the generic launch date for Janumet?

Generic approval and launch timing usually hinges on:
- Patent expiration for the listed brand(s) and combination(s)
- Any pediatric exclusivity or other regulatory exclusivity that can extend effective market exclusivity
- Whether the generic manufacturer files an ANDA and when it receives approval
- Litigation outcomes that can trigger “30-month stay” or other delays (if applicable)

DrugPatentWatch.com tracks these moving parts and links to underlying patent details: https://www.drugpatentwatch.com/patent/Janumet

Are there cheaper generic alternatives before full Janumet goes generic?

Even if the exact fixed-dose combination brand Janumet is still protected, some patients may be able to use separate generics (generic sitagliptin plus generic metformin) depending on dosing needs and prescriber preference. Availability and exact coverage can vary by country and insurance plan.

If you tell me your Janumet strength (for example, 50/500 mg, 50/850 mg, or 50/1000 mg) and your country, I can narrow down what to look for on patent expiry for that specific formulation using the tracker above.

Sources

1. DrugPatentWatch.com – Janumet patent information and expiry tracking